Superconductor Technologies, Inc (NASDAQ:SCON) focuses on RF technology, Celsion Corporation (NASDAQ:CLSN)

Posted by Nathan Alexander May 23, 2013 0 Comment 1312 views


Superconductor Technologies, Inc (NASDAQ:SCON): In Wednesday’s trading session, Superconductor Technologies, Inc (NASDAQ:SCON) dipped 8.02% and closed at $3.90. It opened at $4.20 per share, touched an intraday high, before dropping down to close at $3.90 per share. More than 0.079 million shares were traded in Wednesday’s trading session. This number stood above the average volume of 0.358 million that was measured over a 30-day period.

SCON is involved in the development and commercialization of high temperature superconductor materials and its related technologies. It has commercialized several wireless products utilizing this technology. Superconductor Technologies, Inc (NASDAQ:SCON) is focusing on this technology for use in radio frequency (RF) filters, superconducting power applications and cryocoolers. The company revenue comes from designing, manufacturing and the sale of high-performance infrastructure products. These are used in wireless communication applications. It has three different product lines. All these lines relate to wireless base-stations: AmpLink, SuperPlex and SuperLink. The latter is a reliable and compact receiver front-end wireless filter system. It is used in the elimination of out-of-band interference in wireless base stations. It combines filters with a cooled low-noise amplifier and a cryogenic cooler.

Celsion Corporation (NASDAQ:CLSN): In Wednesday’s trading session, Celsion Corporation (NASDAQ:CLSN) rose 3.19% and closed at $0.970. It opened at $1.02 per share, which was also the intraday high, before dropping down to close at $0.97 per share. Over 5.09 million shares were traded in Wednesday’s trading session. This number stood below the average volume of 2.14 million that was measured over a 30-day period.

Celsion Corporation (NASDAQ:CLSN) is an oncology drug-development company. It focuses on developing treatments for patients who suffer from difficult-to-treat forms of cancer. As of 31 December 2011, ThermoDox, the company’s product is under evaluation in a Phase III clinical-trial. This trial is for primary liver cancer. The other trail that is underway for the same product is a Phase II clinical-trial for colorectal liver metastasis and a Phase II clinical-trial for recurrent, chest-wall breast cancer. This product is a liposomal encapsulation made of doxorubicin. It is a frequently used and approved oncology drug that is used in the treatment of a variety of cancers. Applying localized heat at low hyperthermia temperatures releases this encapsulated doxorubicin from the liposome.


About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment